What HEOR does

HEOR (Health Economics and Outcomes Research LTD) is a UK-incorporated, independent B2B consultancy founded in 2011 that provides integrated market access services to pharmaceutical, biotechnology, and medical device companies across the product development and commercialisation lifecycle. Its service portfolio spans six core areas: Global Market Access, Evidence Review & Synthesis, Health Economic Modelling, Health Technology Assessment, Data Science & Analytics, and Value Communication. The firm operates from Cardiff (headquarters), Bicester, London, and Northern England, with claimed delivery coverage across the UK, Europe, the US, Canada, Central & South America, Asia-Pacific, and the Middle East, and explicit HTA submission experience across 17+ jurisdictions.

The technical stack centres on established health economics methodologies — systematic literature reviews conforming to Cochrane, CRD, and PRISMA, cost-effectiveness and budget impact models, Markov and individual patient-level simulation models, network meta-analyses and matching-adjusted indirect comparisons, with an emerging AI/ML layer that includes neural network-based metamodels for real-time simulation, SHAP-based sensitivity analysis, ML-NMR, predictive analytics, and R/Shiny applications. The team is differentiated by membership in the ISPOR-SMDM Joint Modelling Good Research Practices Task Force and participation in the Mount Hood diabetes modelling challenges, and produces a high-volume peer-reviewed publication output (25 publications across 14 journals in 2025 alone).

HEOR monetises through project-based consultancy engagements priced per scope, with no public pricing or subscription model. The go-to-market is enterprise field sales with direct client engagement, supported by a thought-leadership marketing mix (LinkedIn, industry insights blog, peer-reviewed publications, conference presentations at ISPOR, EASL, Genomics England, and dedicated case studies). Recent strategic positioning includes an SBTi-validated climate commitment and EcoVadis certification, used as procurement-relevant credentials for global pharma clients.

Name

HEOR

Legal name

Health Economics and Outcomes Research LTD

Website

https://heor.co.uk

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

101–250 employees

Short description

HEOR is an independent UK-based health economics and market access consultancy founded in 2011, serving pharmaceutical, biotech, and medical device clients globally with integrated services spanning health economic modelling, evidence synthesis, HTA submissions, data science/AI analytics, and value communication.

Ownership category

akta.pro rank

Product category

Healthcare Market Access Consulting

NAICS

Professional, Scientific, and Technical Services (54), Custom Computer Programming Services (541511)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Computer Programming, Data Processing, Etc. (7370)

akta.pro primary industry

Health Economics & Outcomes Research (HEOR) (HLAIAKAB)

akta.pro secondary industry

Real-World Evidence (RWE) & HEOR for Development (HLAIALAI)

Keywords

• Market access consulting
• Health economics modelling
• Health technology assessment
• Evidence synthesis services
• Pharma value communication

Headquarters

HQ city

Cardiff

HQ country

United Kingdom

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Consulting and Professional Services: Project-based consulting engagements providing integrated market access services spanning the product development and commercialisation lifecycle. Services include market access strategy, evidence generation, health economic modelling, HTA submissions, and value communication.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

HEOR provides integrated market access consultancy services to pharmaceutical, biotechnology, and medical device companies across the product development and commercialisation lifecycle. Its service portfolio covers Global Market Access strategy, Evidence Review & Synthesis (systematic literature reviews), Health Economic Modelling (cost-effectiveness, budget impact, and disease models), Health Technology Assessment submissions, Data Science & Analytics including AI/ML predictive analytics, and Value Communication deliverables.

Product overview

HEOR is an independent market access consultancy providing integrated services across six core areas: Global Market Access, Evidence Review & Synthesis, Health Economic Modelling, Health Technology Assessment, Data Science & Analytics, and Value Communication. These services span the product development and commercialisation lifecycle, supporting clients from early-stage evidence generation through to HTA submissions and post-launch value communication.

Differentiator

Problem solved

Functional benefit

Products and services

• Global Market Access
• Evidence Review & Synthesis
• Health Economic Modelling
• Health Technology Assessment
• Data Science & Analytics
• Value Communication

Quantifiable outcome

• NICE proportionate approach streamlined appraisals by up to 45%
• +1 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability4 records

Feature5 records

Partnerships

One partnership is on record.

• Genomics EnglandcoreStrategic or Co-development Partner · 1 January 2026Collaboration on genomic newborn screening economic analysis following successful award-winning poster presentation at Genomics England Research Summit 2026. The project has opened the door to further collaboration to strengthen and develop the economic analysis of genomic newborn screening value.

Scale indicators4 records

Recent moves6 records

Expansion highlights10 records

Direct peers

• Putnam Associates: Putnam is a specialised strategy and HEOR consultancy serving pharma and biotech with market access strategy, pricing, value communication, and evidence generation. Closely comparable to HEOR on customer base (top pharma), service mix, and project-based delivery model.
• Xcenda: Xcenda is a market access and HEOR consultancy within Cencora (formerly AmerisourceBergen), covering global value dossiers, HTA submissions, health economic modelling, and value communication. Direct peer competing for the same pharma/biotech market access budgets.
• Mtech Access: Mtech Access is a UK-based market access and HEOR consultancy providing health economic modelling, HTA submissions, evidence review, and value communication to pharma clients. Direct competitor with comparable UK roots, service portfolio, and customer profile.
• Analysis Group: Analysis Group operates a Health Economics and Outcomes Research practice alongside its economic and financial consulting, supporting pharma with health economic modelling, real-world evidence, and HTA submissions. Comparable on academic rigour and large-scale pharma client base.
• Evidera: Evidera (now part of Thermo Fisher/PPD) is a dedicated HEOR and market access consultancy offering evidence synthesis, health economic modelling, HTA submissions, and value communication to pharma and biotech. Direct competitor on essentially every core HEOR service line, with larger scale and broader geographic footprint.
• York Health Economics Consortium (YHEC): YHEC is a University of York-owned HEOR consultancy offering evidence synthesis, health economic modelling, and HTA support to pharma and public-sector clients. Direct peer on academic-grade systematic reviews and modelling, particularly relevant for UK and EU HTA engagements.
• RTI Health Solutions: RTI Health Solutions provides health economics, patient-reported outcomes, real-world evidence, and market access services to pharma and medical device clients. Closely aligned on systematic literature reviews, cost-effectiveness modelling, and HTA submission support, with comparable academic-grade publication output.

Broad incumbents

• IQVIA: IQVIA is the largest global life sciences services firm with significant HEOR, real-world evidence, and HTA consulting capability embedded in its Technology & Analytics Solutions. Represents the broad-incumbent threat: pharma often defaults to IQVIA for integrated evidence packages that include HEOR work.
• ICON plc (formerly PRA Health Sciences, includes Syneos): ICON offers a broad clinical and commercial portfolio including HEOR, real-world evidence, and market access via its ICON/PRA and Syneos Commercial Solutions divisions. Competes with HEOR on integrated pharma services contracts, especially with HEOR work bundled into larger CRO engagements.
• Charles River Associates (Life Sciences practice): CRA's Life Sciences practice provides HEOR, market access strategy, and pricing/reimbursement consulting as part of its broader management consulting offering. Competes on high-end pharma strategy mandates where HEOR evidence work is bundled with commercial strategy engagements.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/health-economics-and-outcomes-research-ltd
• Xx.com/heor_ltd

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HEOR